Objective: To determine the association between HIV infection and other risk factors for acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
Introduction
Chronic obstructive pulmonary disease (COPD) affects at least 6.5% of the US population [1] and is a leading cause of morbidity and mortality in the United States, with annual cost estimated at $60-70 billion [1, 2] . Individuals with acute exacerbations of COPD (AECOPD) not only have decreased quality of life [3, 4] , but also increased morbidity and healthcare expenditure [5] [6] [7] [8] [9] .
Although the HIV-infected population has experienced increased survival during the era of combination antiretroviral therapy (cART) [10] , they have also experienced increased prevalence of chronic diseases such as COPD [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Previous studies have shown an increased prevalence of COPD among those with HIV, even after controlling for smoking history [3, 18, 23] , but these earlier studies did not investigate whether HIV was associated with greater rates of AECOPD. A recent study demonstrated an increased risk for AECOPD associated with HIV infection in a study of 167 patients in the AIDS Link to Intravenous Drug Use (ALIVE) cohort [24] . However, although risk factors have been characterized for AECOPD in HIV-uninfected (uninfected) individuals [25] , they have not been well characterized in the HIV-infected population. Understanding AECOPD risk factors in HIV-infected persons is important to improve detection of disease, ensure appropriate care in the acute setting, develop strategies for prevention and to tailor long-term disease management, all of which may differ compared with uninfected persons. Decreasing the rate of AECOPD could improve patient quality of life [3] , influence the rate of change in lung function, as well as decrease healthcare expenditures [2] . Although many factors can impact the development and outcomes of COPD [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , smoking and other substance use, such as unhealthy alcohol [39] and drug use, are modifiable factors that are prevalent among HIVinfected individuals and can potentially impact the outcomes of COPD [40, 41] . Although smoking is an established risk factor for AECOPD in uninfected patients, it is not known whether HIV-infected patients might have an enhanced susceptibility to the harms of smoking given underlying oxidative stress that may be present in the HIV lung [42] . Whether unhealthy alcohol use apart from smoking may have a deleterious effect on pulmonary function remains unclear [41, 43, 44] , and has not been examined as a risk factor for AECOPD in HIV-infected patients [24] . Although some studies show an adverse effect of alcohol on lung function over time, a recent large-scale study demonstrated a protective effect of moderate drinking on lung health [45] . Previous research has also demonstrated increased lung oxidative stress with alcohol use and HIV [5, 43, 44, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] , and negative effects of alcohol on macrophage activation, ciliary clearance, and increasing susceptibility to infection [44, 52, 53, 56, 57] . We hypothesized that both alcohol and smoking may play a more significant role in impacting lung health and risk for AECOPD among HIV-infected than in uninfected individuals. Therefore, in this study, we sought to compare incidence rates of AECOPD among HIV-infected and uninfected patients and to examine the influence of modifiable and nonmodifiable risk factors for AECOPD using data from the Veterans Aging Cohort Study (VACS). We hypothesized that the incidence of AECOPD is higher among HIV-infected patients and that HIV-related immune suppression and modifiable tobacco and unhealthy alcohol use increase risk for AECOPD.
Methods

Design and subjects
We used administrative, clinical, and pharmacy data from the Virtual Cohort in the Veterans Aging Cohort Study (VACS-VC) [58] . The VACS-VC has been described previously [59] . In brief, VACS-VC makes use of several nationally available Department of Veterans Affairs (VA) databases to longitudinally follow and evaluate all veterans with HIV who receive care in the VA system. VACS-VC accesses datasets maintained at the Austin Automation Center (AAC, Austin, Texas, USA), Pharmacy Benefits Management Programme (PBM, Hines, Illinois, USA), VA Information Resources Center (VIReC, Hines, Illinois, USA), and the Decision Support System (DSS). For VACS-VC, HIV-infected participants are identified by HIV International Classification of Diseases, 9th Edition (ICD-9) codes, a process validated against the VA Immunology Case Registry [59] . Using the VA computerized medical record system at the VA Automation Center in Austin, Texas, we identified the first HIV ICD-9 code within the VA as the index date and, for each HIV-infected participant identified, selected two uninfected participants in care at the same time to match the HIV-infected participant on age, race, sex, and Veterans Integrated Service Network (VISN) or region. Because of the limited sample size of HIV-infected women veterans, we identified up to 10 age-, race-, and region (VISN)-matched female controls. In these analyses, we used data from 43 618 HIV-infected veterans identified from 1996 to 2010, and 86 492 age-, race-, sexand region-matched uninfected veterans included in VACS-VC, with last follow-up through October 17, 2010. The Institutional Review Boards of the VA Connecticut Healthcare System and Yale University School of Medicine have approved the VACS-VC study.
Primary outcome
Our primary outcome was time to AECOPD occurring within 2 years of index date. We constructed an algorithm to identify incident AECOPD using the electronic medical record. Similar to other studies [41] , we defined AECOPD as an inpatient or outpatient COPD ICD-9 diagnosis (codes 491.x, 492.x, 493.2, 496.x) within the VA accompanied by prescription dispensed through the VA pharmacy for oral or parenteral steroids or antibiotic within five calendar days of the ICD-9 code. We searched for all antimicrobial classes within the VA; the most frequently identified in these analyses were fluoroquinolones (20%), followed by penicillins (13%), macrolides (13%), sulfa drugs (12%), and cephalosporins (12%). In sensitivity analyses to assess the impact of our outcome definition, we also conducted analyses for an AECOPD definition that did not limit follow-up time to two years; required prescriptions for both steroids and antibiotics; and restricted the cohort to those individuals enrolled after 2000 in order to examine a more recent era.
Risk factors and covariates
Smoking status was obtained from the VA Health Factors database and was categorized as never, past, or current based on most frequent Health Factors smoking data, a method we have previously validated against selfreported data [60] . Diagnosis of unhealthy alcohol use was determined by the presence of one inpatient or two outpatient ICD-9 alcohol-related diagnoses in the baseline window, defined as 12 months prior to and up to 6-months after index date, in VACS-VC [61] . We used the same method to identify drug use disorders. Race was categorized as white, black, Hispanic, or other/unknown based on administrative information, from which we also obtained sex and age. Laboratory (CD4 þ cell counts and HIV viral load) and other pharmacy data (ART use) were obtained from VA administrative databases, using results obtained closest to index date.
Statistical methods and analysis
Patients were followed from index date (i.e. date of entry into the VACS-VC) until time of first AECOPD, death, or last known follow-up within two years of the index date, whichever came first. As the study set out to determine risk factors for AECOPD and not COPD itself, patients with a diagnosis of COPD prevalent at baseline were included in analyses. Patients were not, however, required to have known COPD at baseline to be included and considered at risk for an AECOPD event. We excluded 2430 patients due to having no follow-up time after baseline.
We compared the incidence rates of first AECOPD by HIV status and HIV-related risk factors (namely CD4 þ cell count, HIV viral load, and ART use), and calculated the unadjusted incidence rate per 1000 person-years and used Poisson regression models to determine the unadjusted incidence rate ratio (IRR). Poisson regression is appropriate to use in time to event analysis to generate IRRs. For large samples with low event rates, Poisson models are more efficient to run than Cox Proportional Hazard models and provide similar estimates. We used multivariable Poisson regression models to determine the independent effect of HIV infection on the risk for AECOPD, first comparing all HIV-infected to uninfected individuals, and then stratifying HIV-infected individuals by CD4 þ cell count, adjusting for race, sex, smoking status, and alcohol-related diagnoses. We evaluated whether HIV modifies the relationship between current smoking and AECOPD, and/or the relationship between alcohol use and AECOPD, by evaluating interaction terms in two separate Poisson regression models with all patients. Given significant interaction effects, we also present models stratified by HIV status. All analyses were performed using STATA 13.0 (Stata Corp., College Station, Texas, USA). Statistical tests were two tailed, and we considered P values < 0.05 to be statistically significant.
Results
Baseline characteristics of cohort
The analytic sample consisted of 43 618 HIV-infected and 86 492 uninfected patients, who were mostly male, and largely of black or white race, with a minority of Hispanic and other constituent groups ( Table 1) . The majority were current smokers, with fewer past smokers than never smokers. A diagnosis of COPD was prevalent at baseline in 1919 (4.4%) of HIV-infected and 3461 (4.0%) of uninfected patients in the sample.
Incidence rate of acute exacerbation of chronic obstructive pulmonary disease according to HIV Among VACS-VC participants, 1428 HIV-infected and 2104 uninfected patients had at least one AECOPD over 234 099 person-years of follow-up, with incident rates of 18.8 per 1000 person years for HIV-infected and 13.3 per 1000 person years for uninfected, P < 0.001. The unadjusted rate of AECOPD was significantly higher amongst HIV-infected patients compared with uninfected [IRR 1.41; 95% confidence interval (CI) 1.32-1.51] ( (Table 3a) . Given the strong association with CD4 þ cell count, we then categorized patients according to HIV status and CD4 þ cell count in the same model ( Values shown in data fields are N (%) except for age, CD4 þ , and viral load. Baseline CD4 þ cell count and HIV viral load were missing in 14% of patients. P-value is for comparison of HIV-infected to uninfected. T tests were used to compare normally distributed continuous variables, Wilcoxon rank-sum tests were used to compare nonnormally distributed continuous variables, and x 2 tests were used to compare categorical variables. IQR, interquartile range; SD, standard deviation. analyses, a diagnosis of drug use disorders was not statistically significantly associated with AECOPD in the multivariable analyses and was therefore not included in the final models.
In models to test for effect modification, we found statistically significant interactions between current smoking and HIV (IRR 1.18, 95% CI 1.03-1.35, P ¼ 0.021), and alcohol-related diagnoses and HIV (IRR 1.22, 95% CI 1.04-1.44, P ¼ 0.017) with risk for AECOPD. Thus, we also stratified models by HIV status, in order to evaluate risk factors for AECOPD within each group (Table 4) . Age, race, smoking, and alcohol-related diagnoses remained significant risk factors for AECOPD in both HIV-infected and uninfected patients. Consistent with the significant interaction terms, smoking and alcohol-related diagnoses imparted greater risk for AECOPD among the HIV-infected patients. Lower CD4 þ cell count, HIV viral load greater than 500 copies/ ml, and lack of ART each remained independently associated with greater risk of AECOPD in those with HIV infection when input together in the multivariable model (Table 4 ).
Sensitivity analyses
In sensitivity analyses (see Supplementary tables), results were overall similar. In models containing the variables shown in Table 3b without limiting follow-up time to two years, the IRR for AECOPD was significantly greater for HIV-infected at all CD4 þ cell count strata compared with the uninfected, including those with a CD4 þ cell count of 350 and above (eTable 1). When requiring both antibiotics and steroids to meet a definition of AECOPD, the IRRs were generally higher and were significantly greater for HIV-infected with CD4 þ less than 200 or CD4 þ 200-350 compared with Acute exacerbation of COPD in HIV Depp et al. 459 uninfected (eTable 2). Finally, incidence rates were slightly higher when restricting the cohort to the year 2000 and later, but overall adjusted IRR were similar and inferences were not changed (data not otherwise shown).
Discussion
In this study, we sought to compare incidence rates of AECOPD in HIV-infected to uninfected patients, and to assess risk factors for AECOPD. We found that HIV was independently associated with an increased risk of AECOPD, and that immune suppression, reflected by a lower baseline CD4 þ cell count, was associated with a greater risk of AECOPD. HIV RNA levels above 500 copies/ml and lack of ART in the baseline window were also significantly associated with AECOPD in HIV-infected patients. In addition, AECOPD was strongly associated with current smoking, as well as past smoking, alcohol-related diagnoses, white race, and female sex in both the HIV-infected and uninfected patients. Finally, we found a significant interaction between HIV infection and current smoking, and HIV infection and alcohol-related diagnoses with greater risk for AECOPD. These findings support that severity of immune suppression increases risk for AECOPD, likely through greater risk of infection. Of significant clinical relevance, these data also suggest that the increased risk of AECOPD in HIV may be related to enhanced susceptibility to harms from the modifiable risk factors of smoking and unhealthy alcohol use.
Findings in this study corroborate and extend those of previous studies that have shown a greater prevalence of COPD among the HIV-infected population [23, [62] [63] [64] although we are among the first to investigate risk factors for AECOPD in HIV-infected patients. One prospective, smaller study from the ALIVE cohort showed an increased risk of AECOPD [24] . Similarly, we found that HIV was a risk factor for AECOPD in our cohort, but in contrast to the ALIVE study, we found that a lower CD4 þ cell count at study baseline among HIV-infected individuals, rather than a higher CD4 þ cell count (>350), was an important risk factor for AECOPD. One reason for this difference could be if there were differential rates of misclassification between AECOPD events and pneumonia or other infections in the two studies. However, this possibility is difficult to evaluate as the ALIVE study also did not require chest radiographs to detect AECOPD, but relied on patient self-report of breathing problems requiring an antibiotic or steroid prescription. Although we might have misclassified pneumonia or other infections as AECOPD using administrative data, our sensitivity analyses that required both prescription for steroids and antibiotics in conjunction with a COPD ICD-9 code demonstrated a greater risk for these events in association with HIV infection. As steroids are not part of the routine management of community acquired pneumonia or most other infections, this supports that AECOPD was likely to be also present in these patients. Nonetheless, because 12% of cases were treated with sulfa drugs that can be used for Pneumocystis pneumonia as well as for AECOPD, this might have contributed to finding a greater risk of events in patients with HIV, particularly in those with CD4 þ cell counts below 200.
In this study we also tested the hypothesis that alcohol use is a risk factor for AECOPD, and might confer greater risk in those with HIV. Unhealthy alcohol use and alcohol-related diagnoses are associated with significantly increased risk of hospitalization in HIV-infected compared with uninfected patients, with HIV and alcoholrelated diagnoses having additive effects on risk [65] .
Previous studies have produced conflicting information as to the relationship between unhealthy alcohol use and COPD, some suggesting a relationship and others none [40, 41, 54, 57] . In contrast to a previous study [41] , we found that alcohol-related diagnoses were significantly associated with AECOPD even after controlling for cigarette smoking. Furthermore, the magnitude of risk associated with alcohol-related diagnoses for AECOPD was greater in HIV-infected compared with uninfected individuals, and we found a statistically significant interaction between alcohol-related diagnosis and HIV for risk of AECOPD.
Biological data support that there may be a greater role for alcohol in impacting lung health and risk for AECOPD among HIV-infected than uninfected individuals. Both alcohol and HIV increase lung oxidative stress, which is associated with increased pulmonary disease [5, 43, 44, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . At the same time, alcohol inhibits macrophage activation, increases reactive oxygen species, increases apoptosis, affects ciliary clearance, and increases susceptibility to infection [44, 52, 53, 56, 57] . From a pathophysiologic perspective, infection with HIV coupled with alcohol use could serve as a 'double-hit' to increase susceptibility to exacerbations of lung disease in the setting of systemic inflammation [44, 55] , apart from the known interactions of smoking. Similar effects related to smoking, which is known to increase oxidative stress in the lung, could be contributing to enhanced susceptibility to AECOPD in the setting of HIV infection. Although residual confounding from packyears of smoking and drug use could explain these associations, alcohol may nonetheless have an independent effect on COPD-related medication adherence or risk for infections that can trigger AECOPD, and requires further investigation. This is one of the first studies to examine risk factors for AECOPD in HIV-infected compared with uninfected patients and to do so in a national cohort. Our study has several strengths. The VA healthcare system provides care to the largest population of HIV-infected persons in the United States, and the VACS-VC is the largest such study of HIV-infected individuals with demographically and behaviorally similar uninfected controls. As COPD and other chronic diseases continue to increase in the combination ART era, this is a robust environment for analyzing risk factors for AECOPD. The cohort is geographically diverse with multiple sites across the country, and is racially and ethnically diverse. This allowed us to detect a significantly decreased risk of AECOPD in patients of nonwhite race, a finding that is consistent with other work [66] . However, our current analyses do not allow us to conclude whether nonwhite race is truly protective against AECOPD or whether the relationship between race and AECOPD may be complicated by under-diagnosis and/or competing risk of mortality; additional investigations to understand the relationship between race, ethnicity and manifestations of COPD are required.
Our study also had certain limitations. Pharmacologic and administrative data to detect AECOPD may result in misclassification, as noted above. However, even with full access to chart data, misdiagnosis remains possible as other diseases such as pneumonia or congestive heart failure can present similarly, antibiotics are not always correctly prescribed, and often patients are treated for multiple conditions simultaneously. To comprehensively capture cases of AECOPD, our primary definition of AECOPD required a COPD ICD-9 code in combination with antibiotic or steroid prescription within five days. This approach is similar to other work [41] , although we allowed a five-day window rather than two for the medication prescriptions, because we have found in chart review work within VACS that ICD-9 codes are not necessarily coded on the exact same date in the administrative files as when events occur in the medical record, but are generally more accurate within a three to five day window. Our approach of using antibiotics or steroids is also supported by data evaluating the quality of care delivered for AECOPD, which finds that many patients do not receive both antibiotics and steroids despite recommendations. Only about 60% of patients have been shown to receive optimal quality of care for AECOPD, with 80-85% receiving antibiotics and 80-85% receiving steroids [67] [68] [69] .
To evaluate the robustness of our approach, we evaluated alternative definitions, including requiring both steroids and antibiotics to be prescribed, increasing follow-up time, and limiting our cohort to a more recent era. Our associations with AECOPD were generally similar and showed a consistent association between HIV infection and greater risk for AECOPD, with a significantly greater risk of AECOPD in the HIVinfected when both steroids and antibiotics were required, and a significantly great risk in the HIVinfected with CD4 þ cell counts greater than 350 cells/ml with longer follow-up time.
Other limitations of the VACS-VC include a predominantly male composition with underrepresentation of women, whose AECOPD risk-profile may have significant differences from men. Although the data we used included smoking, using a validated method from VA Health Factors data [60] , we were not able to evaluate for other forms of smoking such as marijuana, second-hand smoke, or pipe-tobacco. To determine drug use, we used diagnoses of drug use disorders, which would miss individuals with lower levels of use or who had not been identified as having such a disorder; we thus have likely underestimated the frequency of drug use. Although we have attempted to control for confounding variables, we cannot rule-out residual confounding to explain the association between HIV and AECOPD. Additionally, we may have missed episodes of AECOPD if patients received care outside of the VA; in prior work, we have found that the likelihood of receiving care outside the VA is generally similar by HIV status and thus is less likely to bias our results finding an association between HIV infection and AECOPD. Finally, we used baseline measures of risk factors and did not include time-updated variables. However, we truncated our follow-up interval to two years to address this limitation. Analyses where we did not truncate follow-up to two years demonstrated a similar association, with an IRR that was larger for the HIVinfected with higher CD4 þ cell counts when compared with the models limited to two years of follow-up.
In summary, we found that the incidence of AECOPD was increased in HIV-infected compared with uninfected patients. Among HIV-infected individuals, a lower CD4 þ cell count was associated with greater risk of AECOPD. Current smoking and unhealthy alcohol-related diagnoses substantially increased the risk of AECOPD, particularly in HIV-infected individuals. Thus, modifiable risk factors to target in future trials to decrease AECOPD in HIV-infected patients include current smoking and unhealthy alcohol use. Improved detection of COPD, earlier recognition of AECOPD, and optimizing maintenance therapy for COPD are also potential targets to explore in future studies that could result in better control of COPD and decreased risk for AECOPD. Intervening on these contributing factors may decrease morbidity and costs associated with COPD, particularly in a vulnerable HIV-infected population.
